In an in vitro drug screen using a Federal Drug Administration-approved drug library, lomofungin, an antifungal drug, was found to strongly decrease ADAM17 activity in hepatocellular carcinoma cells and resulted in enhanced membrane bound MICA expression and inhibited soluble MICA production (261). Here, MICA is linked to hepatocellular carcinoma.